Buchumschlag

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force

Background and aims - This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients. - Methods - Evidence-based review. - Results -...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Averna, Maurizio (VerfasserIn) , Banach, Maciej (VerfasserIn) , Bruckert, Eric (VerfasserIn) , Drexel, Heinz (VerfasserIn) , Farnier, Michel (VerfasserIn) , Gaita, Dan (VerfasserIn) , Magni, Paolo (VerfasserIn) , März, Winfried (VerfasserIn) , Masana, Luis (VerfasserIn) , Mello e Silva, Alberto (VerfasserIn) , Reiner, Zeljko (VerfasserIn) , Ros, Emilio (VerfasserIn) , Vrablik, Michal (VerfasserIn) , Zambon, Alberto (VerfasserIn) , Zamorano, Jose L. (VerfasserIn) , Stock, Jane K. (VerfasserIn) , Tokgözoğlu, Lale S. (VerfasserIn) , Catapano, Alberico L. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: May 2021
In: Atherosclerosis
Year: 2021, Jahrgang: 325, Pages: 99-109
ISSN:1879-1484
DOI:10.1016/j.atherosclerosis.2021.03.039
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.atherosclerosis.2021.03.039
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0021915021001623
Volltext
Verfasserangaben:Maurizio Averna, Maciej Banach, Eric Bruckert, Heinz Drexel, Michel Farnier, Dan Gaita, Paolo Magni, Winfried März, Luis Masana, Alberto Mello e Silva, Zeljko Reiner, Emilio Ros, Michal Vrablik, Alberto Zambon, Jose L. Zamorano, Jane K. Stock, Lale S. Tokgözoğlu, Alberico L. Catapano
Beschreibung
Zusammenfassung:Background and aims - This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients. - Methods - Evidence-based review. - Results - Statin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-high-risk patients with mild to moderately elevated TG levels (>2.3 and < 5.6 mmol/L [>200 and < 500 mg/dL) on a statin, treatment with either a fibrate or high-dose omega-3 fatty acids (icosapent ethyl) may be considered, weighing the benefit versus risks. Combination with fenofibrate may be considered for both macro- and microvascular benefits in patients with type 2 diabetes mellitus. - Conclusions - This guidance aims to improve real-world use of guideline-recommended combination lipid modifying treatment.
Beschreibung:Gesehen am 15.11.2021
Beschreibung:Online Resource
ISSN:1879-1484
DOI:10.1016/j.atherosclerosis.2021.03.039

Ähnliche Einträge